Magnus Nord MD, PhD

Magnus Nord, MD PhD, Assoc Prof, Director Safety Science, Patient Safety, AstraZeneca R&D Magnus holds a position as Director of Safety Science (acting), a Global Enabling Science Function in AstraZeneca Patient Safety. It is a focused group of scientists, physicians, statisticians and informaticians working to shape clinical safety and support decision-making in drug projects. The group collaborates broadly internally and externally including cross-pharma consortia, biotech collaborations, guideline development and academic collaborative studies.

The group is active in four key action areas: Translational Safety, Safety Biomarkers, Safety Informatics and Safety Statistics, and within these Magnus’ focus is on Translational Safety and Safety Biomarkers. Magnus is also chairman and clinical lead of the AstraZeneca Pulmonary Safety Knowledge Group. The Safety Knowledge Groups are internal cross-functional global expert groups covering major organ toxicities. The remit of these groups is broadly divided into project consultations to help drug projects, and enabling activities including facilitation of access to external experts and knowledge.

Magnus carries a broad experience from drug development; before Safety Science he served as Global Safety Physician for several small and large molecule drug projects at various phases in the CNS/Pain Therapy Area, as well as for established products. Prior to this Magnus was Disease Area Expert in Early Clinical Development/ Discovery Medicine in the Respiratory Therapy Area in AstraZeneca. He has a strong academic background in the respiratory field: he has an Associate Professorship in Molecular Medicine at the Karolinska Institute where he led research in the fields of inflammatory lung diseases, and lung damage and biomarkers, in parallel to clinical work.